hVIVO plc
("hVIVO" or the
"Company")
Annual Report & Notice of
AGM
hVIVO plc (AIM & Euronext:
HVO), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, confirms that the Company's
Annual Report and Accounts for the year ended 31 December 2023 and
the Notice of Annual General Meeting ("AGM") will be posted to
shareholders today.
The 2023 Annual Report and Accounts,
the Notice of AGM and accompanying form of proxy are available to
download from the Company's website www.hvivo.com.
The Annual General Meeting will be
held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N
8AF, United Kingdom on 13 May 2024 at 11am (BST).
For further information please
contact:
|
hVIVO plc
|
+44 (0) 20
7756 1300
|
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
|
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward
|
|
|
|
|
|
Peel Hunt LLP (Joint Broker)
|
+44 (0)20
7418 8900
|
|
James Steel, Dr Christopher Golden
|
|
|
|
|
|
Davy
(Euronext Growth Adviser and Joint Broker)
|
+353 (0) 1
679 6363
|
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
|
|
Walbrook PR (Financial PR
& IR)
Stephanie
Cuthbert / Phillip Marriage /
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
|
| |
Notes to
Editors
About
hVIVO
hVIVO plc
(ticker: HVO) (formerly Open Orphan plc) is a rapidly growing
specialist contract research organisation (CRO) and the world
leader in testing infectious and respiratory disease vaccines and
therapeutics using human challenge clinical trials. The Group
provides end-to-end early clinical development services to its
large, established and growing repeat client base, which includes
four of the top 10 largest global biopharma companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which
includes virology, immunology biomarker and molecular testing. The
Group offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London - its
new state-of-the-art facilities opening in Canary Wharf in 2024 is
set to be the world's largest commercial human challenge trial
unit, with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers /
patients for its studies, the Group leverages its unique clinical
trial recruitment capability via its FluCamp volunteer screening
facilities in London and Manchester.